1支降了2325元生长激素纳入医保 医生称生长激素副作用发生率低于3%

Core Viewpoint - The inclusion of growth hormone in the national medical insurance reimbursement list significantly reduces the financial burden on families with children diagnosed with growth hormone deficiency, with the price dropping from 3225 yuan to 900 yuan per injection starting January 1, 2026 [1] Group 1: Financial Impact - The original price of long-acting growth hormone was 3225 yuan, but with insurance reimbursement, it is now only 900 yuan per injection [1] - Families report substantial savings, with one parent indicating that switching to long-acting injections could save thousands of yuan annually [1] Group 2: Treatment Efficacy - Initial treatment results show that children can grow an average of 1 cm per month, with one child growing 11 cm in a year [1] - Early treatment is emphasized as crucial for children diagnosed with growth hormone deficiency, as delays can lead to reduced growth rates [1] Group 3: Safety and Side Effects - The incidence of side effects from growth hormone treatment is reported to be below 3%, which is considered low [1] - Concerns regarding diabetes risk associated with growth hormone are addressed, indicating no clear evidence linking the treatment to increased diabetes risk, with lifestyle factors being more significant [1] Group 4: Parental Guidance - Parents are advised to avoid anxiety regarding their child's height and to communicate effectively with healthcare providers to understand treatment options [1] - The importance of a balanced approach between safety and height expectations is highlighted, encouraging rational perspectives on growth treatment [1]